Although TP53WT primary CLL cells have a functional p53 pathway and are expected to be more sensitive to treatment with MDM2 inhibitors than samples with mutated/deleted TP53, a small subset shows an intermediate response or resistance to RG7388 (Figure 4A,B). This evidence concerns the gene MDM2 and B-cell chronic lymphocytic leukemia.